B6.129P2-Cd44tm1Mak/Cnbc

Status

Available to order

EMMA IDEM:06743
International strain nameB6.129P2-Cd44tm1Mak/Cnbc
Alternative nameCD44
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolCd44tm1Mak
Gene/Transgene symbolCd44

Information from provider

ProviderTak W Mak
Provider affiliationMak Lab, Campbell Family Breast Cancer reseach Institute
Genetic informationTargeting vector replaces 3' end of exon 2 and the entire exon 3 with a neomycin resistance gene in an antisense orientation containing several stop codons for all reading frames.
Phenotypic informationMice were born in Mendelian ratio without any obvious developmental or neurological deficits. Hematological impairment was evidenced by altered tissue distribution of myeloid progenitors with increased levels of colony-forming unit granulocyte-macrophage (CFU-GM) in bone marrow and reduced numbers of CFU-GM in spleen. Fetal liver colony-forming unit spleen and granulocyte colony-stimulating factor mobilization assays, together with reduced CFU-GM in peripheral blood, suggested that progenitor egress from bone marrow was defective.
Breeding historyBackcross into C57BL/6 10X.
References
  • CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.;Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard J J, Ohashi P S, Paige C J, Gutierrez-Ramos J C, Mak T W, ;1997;Blood;90;2217-33; 9310473
  • Absence of the CD44 gene prevents sarcoma metastasis.;Weber Georg F, Bronson Roderick T, Ilagan John, Cantor Harvey, Schmits Rudolf, Mak Tak W, ;2002;Cancer research;62;2281-6; 11956084
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreCNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain
Animals used for archivinghomozygous C57BL/6J

Disease and phenotype information

MGI phenotypes (allele matching)
  • abnormal leukocyte migration / MGI
  • impaired macrophage phagocytosis / MGI
  • liver inflammation / MGI
  • lung inflammation / MGI
  • decreased myocardial infarction size / MGI
  • enhanced coordination / MGI
  • increased mean systemic arterial blood pressure / MGI
  • impaired natural killer cell mediated cytotoxicity / MGI
  • increased circulating tumor necrosis factor level / MGI
  • increased circulating interferon-gamma level / MGI
  • increased circulating interleukin-2 level / MGI
  • decreased transforming growth factor level / MGI
  • decreased sensitivity to induced cell death / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • abnormal circulating cytokine level / MGI
  • decreased activation-induced cell death of T cells / MGI
  • increased susceptibility to induced arthritis / MGI
  • abnormal vasculogenesis / MGI
  • delayed wound healing / MGI
  • peritoneal inflammation / MGI
  • decreased tumor growth/size / MGI
  • abnormal physiological neovascularization / MGI
  • abnormal vascular endothelial cell physiology / MGI
  • decreased susceptibility to kidney reperfusion injury / MGI
  • abnormal miniature excitatory postsynaptic currents / MGI
  • decreased acute inflammation / MGI
  • decreased circulating creatinine level / MGI
  • decreased blood urea nitrogen level / MGI
  • decreased angiogenesis / MGI
  • abnormal vascular endothelial cell morphology / MGI
  • decreased circulating tumor necrosis factor level / MGI
  • increased tumor necrosis factor secretion / MGI
  • abnormal interleukin secretion / MGI
  • increased interleukin-1 beta secretion / MGI
  • increased interleukin-10 secretion / MGI
  • increased interleukin-6 secretion / MGI
  • abnormal chemokine secretion / MGI
  • abnormal circulating chemokine level / MGI
  • abnormal cell morphology / MGI
  • abnormal definitive hematopoiesis / MGI
  • increased susceptibility to parasitic infection / MGI
  • immune system phenotype / MGI
  • abnormal vascular smooth muscle physiology / MGI
  • abnormal cell physiology / MGI
  • increased mitochondria size / MGI
  • abnormal mitochondrial crista morphology / MGI
  • decreased fibroblast proliferation / MGI
MGI phenotypes (gene matching)
  • decreased mast cell number / MGI
  • altered response to myocardial infarction / MGI
  • abnormal cell morphology / MGI
  • decreased mast cell histamine storage / MGI
  • abnormal uterus morphology / MGI
  • thin epidermis / MGI
  • abnormal lipid level / MGI
  • abnormal vasculogenesis / MGI
  • abnormal digestive system physiology / MGI
  • impaired wound healing / MGI
  • impaired macrophage phagocytosis / MGI
  • liver inflammation / MGI
  • lung inflammation / MGI
  • abnormal definitive hematopoiesis / MGI
  • no abnormal phenotype detected / MGI
  • abnormal CD4-positive, alpha beta T cell morphology / MGI
  • abnormal neutrophil physiology / MGI
  • short tibia / MGI
  • impaired skin barrier function / MGI
  • delayed wound healing / MGI
  • decreased myocardial infarction size / MGI
  • abnormal leukocyte migration / MGI
  • peritoneal inflammation / MGI
  • decreased susceptibility to induced arthritis / MGI
  • decreased tumor growth/size / MGI
  • abnormal leukocyte adhesion / MGI
  • abnormal physiological neovascularization / MGI
  • increased susceptibility to induced arthritis / MGI
  • enhanced coordination / MGI
  • decreased cholesterol level / MGI
  • abnormal vascular endothelial cell physiology / MGI
  • decreased susceptibility to kidney reperfusion injury / MGI
  • abnormal miniature excitatory postsynaptic currents / MGI
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • increased mean systemic arterial blood pressure / MGI
  • abnormal CD8-positive, alpha beta T cell morphology / MGI
  • abnormal response to infection / MGI
  • increased susceptibility to parasitic infection / MGI
  • impaired natural killer cell mediated cytotoxicity / MGI
  • decreased acute inflammation / MGI
  • increased acute inflammation / MGI
  • decreased T cell proliferation / MGI
  • digestive/alimentary phenotype / MGI
  • immune system phenotype / MGI
  • hematopoietic system phenotype / MGI
  • abnormal CD4-positive, alpha-beta T cell physiology / MGI
  • abnormal T-helper 1 physiology / MGI
  • abnormal T-helper 2 physiology / MGI
  • choroidal neovascularization / MGI
  • decreased circulating creatinine level / MGI
  • decreased blood urea nitrogen level / MGI
  • abnormal vascular smooth muscle physiology / MGI
  • decreased angiogenesis / MGI
  • decreased susceptibility to type IV hypersensitivity reaction / MGI
  • abnormal cell physiology / MGI
  • abnormal vascular endothelial cell morphology / MGI
  • abnormal involution of the mammary gland / MGI
  • increased diameter of tibia / MGI
  • abnormal osteoclast differentiation / MGI
  • increased circulating tumor necrosis factor level / MGI
  • decreased circulating tumor necrosis factor level / MGI
  • increased tumor necrosis factor secretion / MGI
  • abnormal interleukin secretion / MGI
  • increased circulating interferon-gamma level / MGI
  • increased circulating interleukin-2 level / MGI
  • increased interleukin-1 beta secretion / MGI
  • increased interleukin-10 secretion / MGI
  • increased interleukin-6 secretion / MGI
  • impaired neutrophil recruitment / MGI
  • abnormal chemokine secretion / MGI
  • decreased transforming growth factor level / MGI
  • decreased sensitivity to induced cell death / MGI
  • abnormal epidermal lamellar body morphology / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • abnormal circulating chemokine level / MGI
  • abnormal circulating cytokine level / MGI
  • decreased activation-induced cell death of T cells / MGI
  • increased mitochondria size / MGI
  • abnormal mitochondrial crista morphology / MGI
  • decreased fibroblast proliferation / MGI
  • impaired leukocyte tethering or rolling / MGI

Literature references

  • CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.;Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard J J, Ohashi P S, Paige C J, Gutierrez-Ramos J C, Mak T W, ;1997;Blood;90;2217-33; 9310473
  • Absence of the CD44 gene prevents sarcoma metastasis.;Weber Georg F, Bronson Roderick T, Ilagan John, Cantor Harvey, Schmits Rudolf, Mak Tak W, ;2002;Cancer research;62;2281-6; 11956084

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).